Article Information
History
- November 1, 2020.
Article Versions
- Version 1 (August 14, 2020 - 13:20).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Justin R. Ortiz, MD*,1,†,
- Joanie Robertson*,2,
- Jui-Shan Hsu, MS2,
- Stephen L. Yu, MD1,
- Amanda J. Driscoll, PhD1,
- Sarah R. Williams, MD3,
- Wilbur H. Chen, MD1,
- Meagan C. Fitzpatrick, PhD1,
- Samba Sow, MD4,
- Robin J. Biellik, DrPH5,
- Jean-Marie Okwo-Bele, MD6 and
- Kathleen M. Neuzil, MD1
- 1Center for Vaccine Development and Global Health, 685 W. Baltimore St., University of Maryland School of Medicine, Baltimore, Maryland, USA
- 2PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA
- 3Division of Pulmonary and Critical Care Medicine, 110 S. Paca St, University of Maryland School of Medicine, Baltimore, Maryland, USA
- 4Centre pour le Développement des Vaccins, Ministère de la Santé, BP251Bamako, Mali
- 5Independent Consultant, Tranchepied 10, 1278 La Rippe, Switzerland
- 6Independent Consultant, Chemin de la Poste 6, 1295 Founex, Switzerland
- ↵†CORRESPONDING AUTHOR: Justin R. Ortiz, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore Street, Room 480, Baltimore, MD 21201, USA. Email: jortiz{at}som.umaryland.edu. Phone: +1.410.706.6020.
↵* Authors contributed equally
Posted November 01, 2020.
The operational impact of deploying SARS-CoV-2 vaccines in countries of the WHO African Region
